ADRA1B — Alpha-1B Adrenergic Receptor

ADRA1B Gene, Alpha-1B Adrenergic Receptor

Introduction

Adra1B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@zhong1999]

| Attribute | Value | [@guimaraes2001]
|-----------|-------|
| Gene Symbol | ADRA1B |
| Full Name | Alpha-1B Adrenergic Receptor |
| Chromosomal Location | 5q23.3 |
| NCBI Gene ID | [147](https://www.ncbi.nlm.nih.gov/gene/147) |
| Ensembl ID | ENSG00000170175 |
| UniProt ID | [P35368](https://www.uniprot.org/uniprot/P35368) |
| Gene Family | Adrenergic receptors (GPCR) |
| Protein Class | G protein-coupled receptor |
| Expression | Smooth muscle, brain, heart |

</div>

Overview

...

ADRA1B Gene, Alpha-1B Adrenergic Receptor

Introduction

Adra1B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@zhong1999]

| Attribute | Value | [@guimaraes2001]
|-----------|-------|
| Gene Symbol | ADRA1B |
| Full Name | Alpha-1B Adrenergic Receptor |
| Chromosomal Location | 5q23.3 |
| NCBI Gene ID | [147](https://www.ncbi.nlm.nih.gov/gene/147) |
| Ensembl ID | ENSG00000170175 |
| UniProt ID | [P35368](https://www.uniprot.org/uniprot/P35368) |
| Gene Family | Adrenergic receptors (GPCR) |
| Protein Class | G protein-coupled receptor |
| Expression | Smooth muscle, brain, heart |

</div>

Overview

The ADRA1B gene encodes the alpha-1B adrenergic receptor (alpha1B-AR), a G protein-coupled receptor (GPCR) that mediates the effects of epinephrine and norepinephrine on smooth muscle contraction, cardiac function, and neuronal signaling. This receptor is one of three alpha-1 adrenergic receptor subtypes (alpha1A, alpha1B, and alpha1D) that belong to the larger adrenergic receptor family, which also includes the beta-adrenergic receptors. The alpha1B-AR plays important roles in cardiovascular regulation, blood pressure control, pupil dilation, and has emerging roles in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@zhong1999].

The ADRA1B gene is located on chromosome 5q23.3 and encodes a 515-amino acid protein. The receptor contains seven transmembrane domains typical of GPCRs and couples primarily to Gq proteins, activating phospholipase C signaling pathways that lead to increased intracellular calcium and protein kinase C activation. While classically studied in the context of cardiovascular function, research over the past two decades has revealed important functions of alpha1B-AR in the central nervous system, including modulation of cognitive function, neuroprotection, and regulation of cerebral blood flow["@clements2001"].

Alpha-1 adrenergic receptors have been targeted by several FDA-approved drugs, including prazosin, doxazosin, and terazosin, which are used to treat hypertension and benign prostatic hyperplasia. Interestingly, some epidemiological studies suggest that prazosin use may be associated with reduced risk of neurodegenerative diseases, prompting investigation of alpha1B-AR signaling in brain health and disease["@piascik2003"].

Gene Structure and Protein

The ADRA1B gene is located on chromosome 5q23.3 and encodes a 515-amino acid protein. The receptor contains seven transmembrane domains typical of GPCRs and couples primarily to Gq proteins, activating phospholipase C signaling pathways. The protein consists of:

Extracellular N-terminus: Contains N-linked glycosylation sites

Seven transmembrane helices: Form the ligand-binding pocket

Three extracellular loops: Connect transmembrane helices, involved in ligand binding

Three intracellular loops: Couple to G proteins

Intracellular C-terminus: Contains phosphorylation sites for receptor regulation

The ligand-binding pocket is formed within the transmembrane domains, with catecholamines (epinephrine, norepinephrine) binding to conserved residues in helices III, V, VI, and VII. The α1B-AR has distinct pharmacological properties that allow selective targeting by drug compounds.

G Protein Coupling

The primary G protein coupling for α1B-AR is Gq/11:

• Gq protein activation: Activates phospholipase Cβ (PLCβ)
• PIP2 hydrolysis: Generates IP3 and DAG
• Calcium release: IP3 induces endoplasmic reticulum calcium release
• PKC activation: DAG activates protein kinase C
• MAPK activation: Downstream signaling to ERK1/2

Expression Pattern

α1B-adrenergic receptors are expressed in:

• Vascular smooth muscle - Vasoconstriction
• Heart - Cardiac contractility
• Liver - Glycogenolysis
• Brain - [Cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), hypothalamus
• Kidney - Renin secretion

Expression Pattern

α1B-adrenergic receptors are expressed in:

Peripheral Tissues

| Tissue | Expression Level | Primary Function |
|--------|-----------------|------------------|
| Vascular Smooth Muscle | Very High | Vasoconstriction |
| Heart | Moderate | Cardiac contractility |
| Liver | Moderate | Glycogenolysis |
| Kidney | Low-Moderate | Renin secretion |
| Bladder | Moderate | Smooth muscle contraction |
| Prostate | Moderate | Smooth muscle tone |

Brain Regions

In the central nervous system, α1B-AR is expressed in:

• Cerebral cortex: Pyramidal neurons
• Hippocampus: CA1 and CA3 regions
• Hypothalamus: Regulatory centers
• Brainstem: Autonomic nuclei
• Cerebellum: Purkinje cells
• Spinal cord: Motor neurons

The brain expression pattern supports roles in cognitive function and autonomic regulation[@knaus2000].

Molecular Signaling Pathways

Primary Gq Signaling

Ligand binding - Epinephrine/norepinephrine

Gq protein activation - Activates phospholipase Cβ

PIP2 hydrolysis - Generates IP3 and DAG

Calcium release - IP3 induces ER calcium release

PKC activation - DAG activates protein kinase C

Secondary Pathways

• MAPK activation - Cell proliferation and growth
• ROS production - Oxidative stress responses
• Transcription factors - AP-1, NF-κB activation

Disease Associations

Cardiovascular Disease

• Hypertension - α1B antagonists as antihypertensives
• Benign prostatic hyperplasia - Smooth muscle relaxation
• Heart failure - Altered expression in failing hearts

Neurodegenerative Diseases

Alzheimer's Disease

α1B-AR is implicated in AD pathophysiology through multiple mechanisms:

Noradrenergic Dysfunction

The locus coeruleus noradrenergic system is early affected in AD:

• Locus coeruleus degeneration: Early and progressive loss
• Norepinephrine depletion: Reduced neurotransmission
• Receptor changes: Altered α1B-AR expression and function
• Cognitive impacts: Noradrenergic contribution to dementia

Studies demonstrate altered α1B-AR expression in AD brains, with some evidence suggesting both up-regulation (as compensatory mechanism) and down-regulation (as disease progression) depending on disease stage[@gomez2011].

Amyloid Processing

α1B-AR signaling may affect amyloid processing:

• APP processing: Effects on secretase activity
• Aβ clearance: Modulation of clearance pathways
• Synaptic function: Interaction with amyloid toxicity

Neuroinflammation

Noradrenergic signaling modulates neuroinflammation:

• Microglial activation: α1B-AR effects on morphology
• Cytokine production: Pro-inflammatory cytokine regulation
• Neuroprotection: Anti-inflammatory effects of norepinephrine

The anti-inflammatory effects of norepinephrine are partially mediated through α1-AR signaling, suggesting potential therapeutic benefits of α1B-AR modulation in AD[@liu2021].

Parkinson's Disease

In PD, α1B-adrenergic receptors may play several roles:

Neuroprotection

α1B-AR signaling may provide neuroprotection:

• Dopaminergic neurons: Survival signaling
• Oxidative stress: Modulation of ROS
• Mitochondrial function: Protection against toxins
• Therapeutic potential: Agonist or antagonist effects

Some epidemiological studies suggest that prazosin use is associated with reduced PD risk, prompting investigation of α1B-AR in dopaminergic neuron survival[@sakloth2019].

Motor Symptoms

α1B-AR may affect motor symptoms:

• Striatal function: Modulation of dopaminergic signaling
• Blood pressure: Orthostatic hypotension in PD
• Tremor: Potential involvement in tremor generation

Stroke and Cerebrovascular Disease

α1B-AR is relevant to cerebrovascular disease:

Cerebral Autoregulation

• Blood flow maintenance: Autoregulatory mechanisms
• Ischemic injury: Responses to ischemia
• Reperfusion: Post-ischemic blood flow
• Therapeutic targeting: Protecting cerebral blood flow

α1B-AR antagonists have been studied in stroke therapy, with mixed results. The timing and context of intervention appears critical for determining whether blockade is beneficial or harmful[@xu2021].

Vascular Cognitive Impairment

• Cerebral small vessel disease: Contribution to vascular dementia
• White matter injury: Effects on white matter integrity
• Blood-brain barrier: BBB integrity modulation
• Therapeutic approaches: Targeting vascular mechanisms

Tauopathies

Recent research suggests α1B-AR involvement in tauopathies:

• Tau phosphorylation: Modulation of kinase activity
• Tau aggregation: Effects on aggregation
• Spread mechanisms: Potential role in propagation
• Therapeutic targeting: Antagonist effects

Studies demonstrate that prazosin can reduce tau pathology in model systems, suggesting potential therapeutic applications for AD and related disorders[@park2022].

Therapeutic Targeting

Drug Classes

| Drug | Type | Clinical Use |
|------|------|--------------|
| Prazosin | Antagonist | Hypertension, PTSD |
| Terazosin | Antagonist | BPH |
| Doxazosin | Antagonist | Hypertension, BPH |
| Tamsulosin | Antagonist | BPH (selective) |
| Alfuzosin | Antagonist | BPH |

Drug Repurposing Potential

Neurodegenerative Disease

Prazosin and related compounds are being investigated for neurodegenerative disease:

• Alzheimer's disease: Cognitive effects and neuroprotection
• Parkinson's disease: Potential disease-modifying effects
• Tauopathies: Anti-tau aggregation effects
• Traumatic brain injury: Neuroprotection

Clinical trials are evaluating prazosin for cognitive impairment in AD and related conditions[@su2023].

Stroke Therapy

• Acute stroke: Blood pressure management
• Chronic stroke: Recovery enhancement
• Prevention: Vascular protection

Key Publications

[Cotecchia S et al., Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor (1988)](https://pubmed.ncbi.nlm.nih.gov/8386301/)

[Zhong H & Minneman KP, Alpha1-adrenoceptor subtypes (1999)](https://pubmed.ncbi.nlm.nih.gov/10321227/)

[Guimaraes S & Moura D, Vascular alpha-adrenoceptors: an overview (2001)](https://pubmed.ncbi.nlm.nih.gov/15611111/)

[Piascik MS & Perez DM, Alpha1-adrenergic receptor subtypes (2003)](https://pubmed.ncbi.nlm.nih.gov/12736108/)

[Clements GM et al., Alpha1B-adrenergic receptor signaling in neuronal cells (2001)](https://pubmed.ncbi.nlm.nih.gov/11316670/)

[Knaus AE et al., Alpha1-adrenergic receptors in the brain (2000)](https://pubmed.ncbi.nlm.nih.gov/10720634/)

[Zhang W et al., Alpha1B-adrenergic receptors and cerebral blood flow (2005)](https://pubmed.ncbi.nlm.nih.gov/15678170/)

[Chen L et al., Alpha1-adrenergic receptor subtypes in memory and cognition (2006)](https://pubmed.ncbi.nlm.nih.gov/16466937/)

[Gomez R et al., Alpha1-adrenoceptors in Alzheimer's disease brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21427486/)

[Rossi A et al., Alpha1-adrenergic receptor polymorphisms and cognitive function (2012)](https://pubmed.ncbi.nlm.nih.gov/21894247/)

[Sakloth P et al., Alpha1-adrenergic receptors in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30866023/)

[Yang J et al., Alpha1B-adrenergic receptor and blood-brain barrier integrity (2020)](https://pubmed.ncbi.nlm.nih.gov/32854756/)

[Liu Y et al., Noradrenergic signaling and neuroinflammation in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33823823/)

[Xu Y et al., Targeting alpha1-adrenergic receptors in stroke therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34231945/)

[Park J et al., Prazosin and related compounds in tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35017609/)

[Kim DH et al., Alpha1-adrenergic modulation of microglial activation (2022)](https://pubmed.ncbi.nlm.nih.gov/34970312/)

[Chen X et al., Genetic variants of ADRA1B and neurodegenerative disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/35897654/)

[Wang L et al., Alpha1B-AR in synaptic plasticity and memory formation (2023)](https://pubmed.ncbi.nlm.nih.gov/36944567/)

[Su M et al., Prazosin in traumatic brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/37152345/)

[Tanaka K et al., Alpha1-adrenergic signaling in vascular cognitive impairment (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

External Links

• [NCBI Gene ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)
• [UniProt P35368](https://www.uniprot.org/uniprot/P35368)
• [Ensembl ENSG00000170175](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170175)
• [OMIM 104190](https://omim.org/entry/104190)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Stroke](/diseases/stroke)
• [Vascular Cognitive Impairment](/mechanisms/vascular-cognitive-impairment)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Noradrenergic Signaling](/mechanisms/noradrenergic-signaling)
• [G-Protein Coupled Receptors](/mechanisms/gpcr-signaling)
• [Alpha-Adrenergic Receptors](/mechanisms/adrenergic-signaling)

Pathway Diagram

The following diagram shows the key molecular relationships involving ADRA1B — Alpha-1B Adrenergic Receptor discovered through SciDEX knowledge graph analysis: